Work

Supplementary Figure 2 from Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 36K, Cells were treated with PTEN siRNA for 48 h, and then treated with PLX4720 at doses near the individual IC50s for a further 72 h. (HT29: 0.01�M, Colo205: 0.05�M, Vaco5: 1 �M). HT29 contains an atypical and poorly characterized mutation (P449T) outside of the hotspots in the kinase and helical domains. siPTEN did not impact PLX4720 sensitivity in Vaco5, which contains a known activating mutation in the helical domain of PIK3CA.

DOI: 10.1158/1078-0432.22445844

Authors: Muling Mao, Feng Tian, John M. Mariadason, Chun C. Tsao, Robert Lemos, Farshid Dayyani, Y.N. Vashisht Gopal, Zhi-Qin Jiang, Ignacio I. Wistuba, Xi M. Tang, William G. Bornman, Gideon Bollag, Gordon B. Mills, Garth Powis, Jayesh Desai, Gary E. Gallick, Michael A. Davies, Scott Kopetz

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361881548

Cites:

Cited by:

Related to: 10